Current controversies in acromegaly care
Recommendations
As issued by the authors
Delayed diagnosis persists, associated with increased morbidity; artificial intelligence may reduce diagnostic delay, but ethics, privacy and application in diverse populations present challenges
Symptom variability occurs with long-acting somatostatin receptor ligands (SRLs) and other regimens even with biochemical control; discordance between biochemical and clinical response requires consideration of signs and symptoms in addition to IGF-1 levels
Premenopausal women with uncontrolled acromegaly are at risk of increased pregnancy complications; data on fertility, pregnancy and fetal effects of acromegaly drugs are limited to case reports and series; pregnancies typically have good maternal and fetal outcomes
Predictive algorithms for first-line SRL response are validated in investigational contexts, but implementation, accuracy and standardization in clinic practice are undetermined
Alternative dosing regimens show promise for decreasing medication burden, cost, and/or improving control
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →